Skip to main content
Glama

Mhra Drug Safety Update

mhra_drug_safety_update
Read-onlyIdempotent

Articles from Drug Safety Update, the MHRA monthly bulletin that tells UK prescribers about new safety signals: new contraindications, updated warnings, restricted indications and monitoring advice for medicines already in use. The UK counterpart to an FDA drug safety communication. Answers "what new safety advice has the MHRA issued about this medicine". Returns title, publication date, summary and GOV.UK URL; filter by free text and date range, then pass a URL to mhra_alert_detail for the full article.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
limitNoArticles to return, 1-100 (default 20).
queryNoFree-text search, e.g. a drug name ("metformin", "domperidone") or a safety topic ("angioedema").
offsetNoResults to skip, for paging (default 0).
published_toNoLatest publication date, YYYY-MM-DD.
published_fromNoEarliest publication date, YYYY-MM-DD.

Schema Changelog

Changes observed during successful MCP inspections.

  1. First observed

TDQS

A4/5.0
Behavior3/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already declare readOnlyHint, openWorldHint, idempotentHint, and destructiveHint=false, covering the safety profile. The description adds useful context about the type of content (safety signals) and the output fields, but does not disclose pagination behavior or that results are limited to monthly bulletins, which is a gap given annotations are broad.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness5/5

Is the description appropriately sized, front-loaded, and free of redundancy?

Two sentences with zero waste, front-loading the purpose and directly stating what it returns and how to filter. The description is dense but efficient, and the mention of passing the URL to a sibling is a valuable routing hint.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness4/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

Given the tool's moderate complexity (5 params, no output schema), the description covers purpose, usage, returns, and follow-up sufficiently. No output schema exists, so the description compensates by listing return fields (title, date, summary, URL). It could mention default limit and pagination, but these are in the schema, so minor gap only.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters3/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema description coverage is 100%, so all 5 parameters are documented with their types and descriptions. The description adds value by explaining the query parameter's use with examples and clarifying the free-text nature, but does not add much beyond the schema, hence baseline 3 is appropriate.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

States the specific source (Drug Safety Update), the audience (UK prescribers), the type of content (new safety signals), and explicitly names the UK FDA counterpart. It also summarizes returns (title, date, summary, URL) and distinguishes from sibling mhra_alert_detail by pointing to that tool for full articles.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

Clearly describes when to use (to answer 'what new safety advice has the MHRA issued about this medicine') and how to filter, and mentions the sibling mhra_alert_detail for follow-up. However, it does not explicitly state when NOT to use this tool versus mhra_safety_alerts or other research tools, leaving some ambiguity for an agent.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

Try in Browser

Glama MCP Gateway

Add one secure layer between your agents and this server.